Therapeutic opportunities for muscarinic receptors in the central nervous system.
about
Organophosphates dysregulate dopamine signaling, glutamatergic neurotransmission, and induce neuronal injury markers in striatumLeveraging the cortical cholinergic system to enhance attentionSubtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersA subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviorsAllosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learningSystematic Review of Pharmacological Properties of the Oligodendrocyte Lineage"Manganese-induced neurotoxicity: a review of its behavioral consequences and neuroprotective strategies"Application of Neurochemical Markers for Assessing Health Effects after Developmental Methylmercury and PCB CoexposureThe antipsychotic potential of muscarinic allosteric modulationM4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition.A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learningSynthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists.Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moietiesSynthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen.Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl)phenyl)benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists.All muscarinic acetylcholine receptors (M1-M5) are expressed in murine brain microvascular endothelium.Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation, and differentiation.Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function.M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells.Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents.Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal modelsMuscarinic receptor activation elicits sustained, recurring depolarizations in reticulospinal neurons.Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome.Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficitsEnhanced muscarinic M1 receptor gene expression in the corpus striatum of streptozotocin-induced diabetic rats.Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation.The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtypeIntact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method.Cholinergic functioning in stimulant addiction: implications for medications development.Muscarinic acetylcholine receptors as effector sites for present and future therapeutic applications: focus on non-neural cholinergic systems.New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.M1 muscarinic acetylcholine receptor in Alzheimer's diseaseRecent updates in the treatment of neurodegenerative disorders using natural compounds.Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode.Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.Synthesis and structure-activity relationships of allosteric potentiators of the m(4) muscarinic acetylcholine receptor.Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor.
P2860
Q23918184-F28CC407-1C32-4674-BD94-BE3D0A129ED9Q24598925-C8E865E1-C335-43AA-8DC3-325FCDD55107Q24605472-93180751-98AC-4A07-97F7-0F2238CE9416Q24645678-BF86A78B-C50A-482E-9EA3-778593478896Q24649568-744B5999-9BDE-4023-9ABD-E6F787FB327EQ24657785-A17ECD73-251D-4F13-9BB5-DCA09C2E3710Q26768210-C0577B4C-E672-4FDB-B3E8-74D765CA7952Q28067566-B29552C0-B8B9-4307-ACE4-528021210F29Q28397719-B2088B91-B854-4A91-84C3-C5FB8721FE83Q28603221-10028965-2F01-47D9-96B0-72C0755D2E23Q30467341-B19C21E2-8B0C-4290-B083-95562DC9FE7BQ30488913-B2D8BD8F-63FE-4E75-8A0F-80719FB55BFDQ33313445-1105094D-A4D3-4AFA-8A4E-BE1593644A3FQ33370832-B9C5DEFF-1DD6-4DEB-97E9-D5893F8F4706Q33373225-7F4F2F44-2348-469C-B3A3-885D58ECD499Q33536927-2092C011-C2EC-40A6-956E-01509A33C7B0Q33895150-B0528812-2929-4F31-89E8-6808481C1745Q34018175-016FEEE2-D6A7-43AD-A720-9ACBD5F3C9DDQ34552778-D03AE9C0-C2E7-4AFF-AB6E-135DFA569094Q34620313-10F83473-2C67-4A05-BFA7-791E0ECB5EDAQ34622385-35757B3F-FB05-4338-8DDE-18C57A73A170Q35776844-AEBEC417-3697-403E-8ACA-94FDE13B22C7Q36099440-07BB0B11-E126-43FC-916C-E6EC6E483182Q36678757-D1582B31-1C1E-46B5-8F13-5EA1E60ABE56Q36766834-96DE4C48-6FAB-45DD-A9B7-D279077D5C9CQ37025888-03E6E6C4-D96B-43DC-89D7-DBD4C5B3479BQ37194006-34271575-2754-482B-93CD-186E011CA918Q37248290-858E71DD-B207-4C50-8044-18AE8911931FQ37309784-0C514D9A-A854-43F8-8893-FBD64A2F4367Q37506679-D7A86CCF-F80F-4B9B-81BF-F7FBF6726EE4Q37618780-CAE13EF6-D659-496C-9633-C9689C7AB7D0Q37689776-1C39B11A-73C3-4665-A647-984918D775B9Q38099889-01CDB49B-08C5-4B00-A704-D5AF63D727CCQ38150484-FDC6B42F-E8CF-492C-9324-3997915B3D90Q38192962-ECC7FE4B-A41F-4761-84ED-1B248F65C981Q38215181-E8AA0CA9-AE55-49DC-BCE2-E60AD6454659Q39222571-A31F0DF5-0808-472D-B7AF-F1A5909E6C12Q39797234-B5D0EB9F-2A96-4D40-B7EF-7555E0280910Q41149576-49528664-A120-4C8D-A272-B61BE360D86DQ42108826-6BF2D37C-F016-4EFE-808F-D3DC9D681082
P2860
Therapeutic opportunities for muscarinic receptors in the central nervous system.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Therapeutic opportunities for muscarinic receptors in the central nervous system.
@ast
Therapeutic opportunities for muscarinic receptors in the central nervous system.
@en
Therapeutic opportunities for muscarinic receptors in the central nervous system.
@nl
type
label
Therapeutic opportunities for muscarinic receptors in the central nervous system.
@ast
Therapeutic opportunities for muscarinic receptors in the central nervous system.
@en
Therapeutic opportunities for muscarinic receptors in the central nervous system.
@nl
prefLabel
Therapeutic opportunities for muscarinic receptors in the central nervous system.
@ast
Therapeutic opportunities for muscarinic receptors in the central nervous system.
@en
Therapeutic opportunities for muscarinic receptors in the central nervous system.
@nl
P2093
P356
P1476
Therapeutic opportunities for muscarinic receptors in the central nervous system.
@en
P2093
P304
P356
10.1021/JM990607U
P407
P577
2000-11-01T00:00:00Z